👉 Tune in on Soundcloud or Spotify

At Immuvera, we are pioneering a new immunotherapy for cancer in dogs – with the goal of preventing and treating lung metastases. In 2026, we will launch a randomized clinical trial with 40 dogs across 20 veterinary clinics in Europe. Looking ahead, our ambition is clear: a deal-exit in late 2027, followed by regulatory approval and market introduction in 2029 – bringing a much-needed treatment to dogs and their owners worldwide.

As part of this next chapter, we are raising new funding through Folkeinvest.

👉 Follow our case here: https://folkeinvest.no/kampanjer?kommer-snart=immuvera-therapeutics